Investor Relations - Organicell

Investor Relations

Investor Relations

SEC Filings

Organicell Regenerative Medicine, Inc. 2022 10-K dtd March 16th 2022 (sec.report)

Organicell Regenerative Medicine, Inc. 2022 10-K dtd February 14th 2022 (sec.report)

Organicell Regenerative Medicine, Inc. 2022 8-K dtd February 8th 2022 (sec.report)

Organicell Regenerative Medicine, Inc. 2022 8-K dtd January 13th 2022 (sec.report)

Organicell Regenerative Medicine, Inc. 2021 8-K dtd December 29th 2021 (sec.report)

Organicell Regenerative Medicine, Inc. 2021 8-K dtd November 9th 2021 (sec.report)

Organicell Regenerative Medicine, Inc. 2021 8-K dtd November 5th 2021 (sec.report)

Organicell Regenerative Medicine, Inc. 2021 8-K dtd November 2nd 2021 (sec.report)

Organicell Regenerative Medicine, Inc. Schedule 14C Information Statement dtd October 5th 2021 (sec.report)

Organicell Regenerative Medicine, Inc. Quarterly Report 10-Q (sec.report)

Organicell Regenerative Medicine, Inc. 2021 8-K dtd August 31st 2021 (sec.report)

Press Release

Organicell and Proxima CRO Set to Open Clinical Trial for Long Hauler COVID-19 Patients

Organicell Regenerative Medicine, Inc. Provides Updates of Clinical Trial Activities

Organicell Announces Approval to Uplist Common Stock to OTCQB

logo_footer

LET’S STAY CONNECTED

Newsletter

© 2020 Organicell ™ | All rights reserved. Privacy Policy.